| [December 15, 2017] |
 |
Increlex 2016-2017 U.S. Promotional Report - Research and Markets
The "Increlex
2016 U.S. Promotional Report" report has been added to Research
and Markets' offering.
The 5 Key Questions Addressed by this Report:
-
How many physicians were reached by Increlex through personal
promotion in 2016 to drive use within the Primary IGF-1 Deficiency?
-
What promotional mix was leveraged (e.g., sales rep detailing,
physician education, and paid speaking) and what was the median spend
on each type of activity?
-
How does Ipsen's depth of coverage vary within key specialties (e.g.,
Pediatric Medicine, Endocrinology, and Physical Medicine and
Rehabilitation) and hw does this compare to the overall set of
rep-accessible physicians?
-
How often are physicians receiving paid meals for Increlex throughout
the year (e.g., monthly, quarterly, annually)?
-
Who were the most detailed prescribers and top paid speakers for
Increlex in 2016?
Data Sources and Methodology:
-
We leverage company-reported financial transaction data disclosed
through CMS Open Payments. This data set captures all transfers of
value (e.g., speaking fees, consulting fees, travel, education, and
meals) made on behalf of a drug or device manufacturer to a physician.
Currently, 42 months of longitudinal data is available - covering
payments to more than 900,000 U.S. healthcare professionals.
-
Over 200 paid interactions across 100 physicians made on behalf of
Increlex were carefully examined to support our analysis.
For more information about this report visit https://www.researchandmarkets.com/research/tx58cr/increlex?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20171215005472/en/
[ Back To TMCnet.com's Homepage ]
|
